US FDA advisers back Replimune skin cancer drug trial data (updated)
US FDA panel backs Replimune skin cancer drug study data
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
U.S. STOCKS ON THE MOVE-Visa, CMS Energy, Ecolab
U.S. STOCKS ON THE MOVE-Visa, CMS Energy, Ecolab
U.S. STOCKS ON THE MOVE-American Tower, Xylem, Core Scientific
Replimune falls after FDA staff flags efficacy concerns about skin cancer therapy
Replimune falls after FDA staff flags efficacy concerns about skin cancer therapy
US FDA staff cast doubt on Replimune cancer drug's benefit; shares slide (updated)
US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting
Replimune Group Inc reports results for the quarter ended March 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Replimune slips as FDA accepts skin cancer drug review, but advisory panel adds risk
Replimune Group Inc expected to post a loss of 71 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
U.S. RESEARCH ROUNDUP-Palomar Holdings, Replimune Group, Snowflake
Brief: Replimune Group Says Rp1 Plus Nivolumab Achieves Median Overall Survival Of 32.9 Months In Anti-Pd-1-Failed Melanoma